Liver News and Research

RSS

Drug trial horror gave victim '4 months of hell'

One of the six volunteers who were left critically ill when a drug trial went horribly wrong has spoken out about his ordeal.

28 Jun 2006

Liver cancer is likely caused by cycles of liver cell death and renewal

Research at the University of California, San Diego (UCSD) School of Medicine shows that liver cancer is likely caused by cycles of liver cell death and renewal.

27 Jun 2006

FDA approves Prezista (darunavir)

FDA approves Prezista (darunavir), a new drug for adults whose infection with the human immunodeficiency virus (HIV) has not responded to treatment with other antiretroviral drugs.

26 Jun 2006

From DNA to RNA to protein

Of the thousands of proteins produced in our cells, few are as important as the enzyme RNA polymerase (RNAP), which has the unique ability to faithfully copy genetic information from DNA.

18 Jun 2006

First drug treatment for late-stage cervical cancer approved

FDA has approved a combination of Hycamtin (topotecan hydrochloride) and cisplatin for use as the first drug treatment for women with late-stage cancer of the cervix.

18 Jun 2006

Protein represents new target in the treatment of diabetes

According to a new study elevated levels of a molecule called RBP4 (retinol binding protein 4) forecast the early stages of the development of insulin resistance, a major cause of type 2 diabetes as well as cardiovascular disease and metabolic syndrome.

18 Jun 2006

Elevation of fat-derived molecule foretells early insulin resistance

A study in the June 15 issue of The New England Journal of Medicine (NEJM) reveals that elevated levels of a molecule called RBP4 (retinol binding protein 4) can foretell early stages in the development of insulin resistance.

14 Jun 2006

Major intestinal surgery may boost the chances of subsequent vitamin A deficiency

Major intestinal surgery, including stomach reduction for obesity, may boost the chances of subsequent vitamin A deficiency, suggests a small study published in the British Journal of Ophthalmology.

14 Jun 2006

New drug will treat those winter blues

The U.S. Food and Drug Administration (FDA) has given it's approval for a drug to treat a condition known as Seasonal Affective Disorder (SAD).

14 Jun 2006

Coffee may help prevent cirrhosis of the liver

Researchers in the U.S. suggest that drinking coffee may help protect against alcohol-related cirrhosis of the liver.

12 Jun 2006

Quebec's first successful combined heart/liver transplant

Doctors at the McGill University Health Center have announced Quebec's first successful combined heart/liver transplant.

9 Jun 2006

Liquorice compounds could be a key component for cheaper, more effective liver cancer treatment

Liquorice compounds could be a key component for cheaper, more effective liver cancer treatment, reports Chemistry & Industry magazine.

8 Jun 2006

Impact of obesity on treatment of chronic hepatitis C

According to a new study, obese patients chronically infected with the hepatitis C virus (HCV) and treated with combination drug therapy may have better outcomes if the underlying abnormalities caused by excessive fat tissue are corrected.

6 Jun 2006

Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia

The overall survival of most people with chronic myelogenous leukemia (CML) treated with imatinib (Gleevec, STI-571) is extremely high and the relapse rate is quite low, according to new data from a study out of the Oregon Health & Science University Cancer Institute.

6 Jun 2006

Evidence is strong that green tea lowers the risk for a number of chronic diseases

There is a lower incidence of cardiovascular disease and cancer in Asia where people smoke heavily, which may be accounted for by high consumption of tea, particularly green tea, according to a review article published by a Yale School of Medicine researcher.

6 Jun 2006

Study shows skin rash in patients treated for liver cancer determines survival

In a study of a new chemotherapy drug for liver cancer, researchers found that the development of a skin rash correlated directly with the patient's response to treatment.

6 Jun 2006

Addition of gemcitabine to standard postoperative treatment increased pancreatic cancer patients' survival by 50 percent

Adding the cancer-fighting drug gemcitabine to standard therapy after surgery significantly improves survival for patients with the most common form of pancreatic cancer, according to a new multicenter study led by a University of Maryland radiation oncologist.

6 Jun 2006